Mark Cuban Cost Plus Drugs Can Save You Plenty
Synopsis: Mark Cuban Cost Plus Drug Company, commonly known as Cost Plus Drugs, offers safe medicines at the lowest possible price. The studied nine commonly-prescribed urological drugs - tamsulosin, finasteride, oxybutynin, alfuzosin, solifenacin, tolterodine, sildenafil, tadalafil, and abiraterone - are used to treat conditions including prostate cancer, overactive bladder, and prostate enlargement. We found that if the U.S. government used Mark Cuban's cost-plus drug pricing model to supply urological drugs to Medicare patients, they would save taxpayers an estimated $1.29 billion.
- Mark Cuban Cost Plus Drug Company (MCCPDC)
Mark Cuban Cost Plus Drug Company (MCCPDC), doing business as Cost Plus Drugs, is a public benefit corporation (PBC) with its primary headquarters located in Dallas, Texas. The company is focused on the pharmacy distribution of drugs with a stated goal to lower the prices for generic drugs by removing intermediaries and moving to a cost-plus pricing strategy. As of June 2022, the company has a selection of over 100 generic drugs. The drugs are sold for a price equivalent to the company's cost plus a 15% markup and a $3 pharmacy service fee. The company currently ships to all 50 U.S. States.
Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model - The Journal of Urology.
A new drug company founded by entrepreneur Mark Cuban could save patients $1.29 billion a year based on 2020 Medicare Part D expenditures on just the nine most popular urological drugs, according to a study published in the Journal of Urology.
The study, led by Vanderbilt University Medical Center (VUMC) researchers, examined the potential savings if Medicare prices for generic drugs were as low as those offered under the Mark Cuban Cost Plus Drug Company, which provides a standard template pricing of the cost of manufacturing the drug plus a 15% markup, plus standard $5 fees for dispensing and $3 fees for shipping.
"We found that if the U.S. government used Mark Cuban's cost-plus drug pricing model to supply urological drugs to Medicare patients, they would save taxpayers an estimated $1.29 billion," said lead author Ruchika Talwar, MD, a fellow in Urologic Oncology at VUMC.
"It means that patients would be able to get their drugs more affordably, but also means that taxpayer funds could go toward other important issues and hopefully save us all some money in general."
The studied nine commonly-prescribed urological drugs - tamsulosin, finasteride, oxybutynin, alfuzosin, solifenacin, tolterodine, sildenafil, tadalafil, and abiraterone - are used to treat conditions including prostate cancer, overactive bladder, and prostate enlargement.
For the 90-day prescription prices, all drugs generated cost savings for Medicare, ranging from 48.7% to 99.2%. The savings for abiraterone alone amounted to $656 million, or nearly 52% of all potential Medicare savings for urological drugs in both 30-day and 90-day prescription models. Abiraterone is used to treat prostate cancer that has spread to other parts of the body by blocking testosterone, which is the hormone that drives prostate cancer growth.
"Just by changing the way one commonly prescribed drug (abiraterone) was purchased, we could convey a benefit of more than $650 million in cost savings to taxpayers," Talwar said. "The impact of this could be astronomical across all cancers ... any sort of oral, generic drug available through Mark Cuban's company can be much cheaper for many patients, not just Medicare patients, through this program. And taxpayers are the ones who fund Medicare drug spending."
"When Dr. Talwar approached me to move this project forward, I had little idea of its possible impact," said co-author Sam S. Chang, MD, MBA, Patricia and Rodes Hart Endowed Professor of Urologic Surgery and VUMC Chief Surgical Officer, Vanderbilt Ingram Cancer Center.
"Dr. Talwar's interest, investigation, and efforts have gained national attention and increased the need for policy initiatives to decrease medical costs. Under her leadership, the team's future work outlines the financial burden of common cancer therapies on our patients and the possible next steps forward," he said.
Resources That Provide Relevant Related Information
- Mark Cuban's Cost Plus Drug Company Could Save Taxpayers Millions
- Cost Plus Drugs : Lowest Prices on Lifesaving Prescriptions
This peer reviewed publication pertaining to our Pharmaceutical Information section was selected for circulation by the editors of Disabled World due to its likely interest to our disability community readers. Though the content may have been edited for style, clarity, or length, the article "Mark Cuban Cost Plus Drugs Can Save You Plenty" was originally written by Vanderbilt University Medical Center, and submitted for publishing on 2023/02/11 (Edit Update: 2023/06/12). Should you require further information or clarification, Vanderbilt University Medical Center can be contacted at the vumc.org website. Disabled World makes no warranties or representations in connection therewith.
📢 Discover Related Topics
👍 Share This Information To:
𝕏.com Facebook Reddit
Page Information, Citing and Disclaimer
Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page.
Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/cost-plus-drugs.php">Mark Cuban Cost Plus Drugs Can Save You Plenty</a>
Cite This Page (APA): Vanderbilt University Medical Center. (2023, February 11). Mark Cuban Cost Plus Drugs Can Save You Plenty. Disabled World. Retrieved February 26, 2024 from www.disabled-world.com/medical/pharmaceutical/cost-plus-drugs.php
Disabled World provides general information only. Materials presented are never meant to substitute for qualified professional medical care. Any 3rd party offering or advertising does not constitute an endorsement.